R&D Jennifer Schneider’s insights on immunotherapy at JP Morgan ... Jonah Comstock caught up with Jennifer Schneider, CEO of Centauri Therapeutics, in San Francisco in January during the JP Morgan Healthcare Conference
News FDA approves higher Wegovy dose via 4th priority voucher The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
